Binding of longer Aβ to transmembrane domain 1 of presenilin 1 impacts on Aβ42 generation

Molecular Neurodegeneration

Takeshi Iwatsubo²  Taisuke Tomita⁴  Tohru Fukuyama⁵  Satoshi Yokoshima⁵  Takuya Higo¹  Satoko Osawa³  Aya Tominaga³  Naoaki Shimada¹  Yu Ohki³ 

[1] Department of Synthetic Natural Chemistry, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan;Department of Neuropathology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan;Department of Neuropathology and Neuroscience, Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan;Core Research for Evolutional Science and Technology, Japan Science and Technology Agency, Bunkyo-ku, Tokyo 113-0033, Japan;Laboratory of Natural Products Chemistry, Graduate School of Pharmaceutical Sciences, Nagoya University, Nagoya 464-8601, Japan

关键词: γ-Secretase modulator;    Intramembrane proteolysis;    Alzheimer disease;    Secretases;    Presenilin;   

Others  :  861721
DOI  :  10.1186/1750-1326-9-7

 received in 2013-11-08, accepted in 2014-01-10,  发布年份 2014

【 摘 要 】

Background

Amyloid-β peptide ending at 42nd residue (Aβ42) is believed as a pathogenic peptide for Alzheimer disease. Although γ-secretase is a responsible protease to generate Aβ through a processive cleavage, the proteolytic mechanism of γ-secretase at molecular level is poorly understood.

Results

We found that the transmembrane domain (TMD) 1 of presenilin (PS) 1, a catalytic subunit for the γ-secretase, as a key modulatory domain for Aβ42 production. Aβ42-lowering and -raising γ-secretase modulators (GSMs) directly targeted TMD1 of PS1 and affected its structure. A point mutation in TMD1 caused an aberrant secretion of longer Aβ species including Aβ45 that are the precursor of Aβ42. We further found that the helical surface of TMD1 is involved in the binding of Aβ45/48 and that the binding was altered by GSMs as well as TMD1 mutation.

Conclusions

Binding between PS1 TMD1 and longer Aβ is critical for Aβ42 production.

【 授权许可】

   
2014 Ohki et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Holtzman DM, Morris JC, Goate AM: Alzheimer's disease: the challenge of the second century. Sci Transl Med 2011, 3:77sr71.
• [2]Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y: Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 1994, 13:45-53.
• [3]De Strooper B, Annaert W: Novel research horizons for presenilins and gamma-secretases in cell biology and disease. Annu Rev Cell Dev Biol 2010, 26:235-260.
• [4]Takasugi N, Tomita T, Hayashi I, Tsuruoka M, Niimura M, Takahashi Y, Thinakaran G, Iwatsubo T: The role of presenilin cofactors in the gamma-secretase complex. Nature 2003, 422:438-441.
• [5]Tomita T, Iwatsubo T: Structural biology of presenilins and signal peptide peptidases. J Biol Chem 2013, 288:14673-14680.
• [6]Takami M, Nagashima Y, Sano Y, Ishihara S, Morishima-Kawashima M, Funamoto S, Ihara Y: gamma-Secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment. J Neurosci 2009, 29:13042-13052.
• [7]Sato C, Morohashi Y, Tomita T, Iwatsubo T: Structure of the catalytic pore of gamma-secretase probed by the accessibility of substituted cysteines. J Neurosci 2006, 26:12081-12088.
• [8]Morohashi Y, Tomita T: Protein trafficking and maturation regulate intramembrane proteolysis. Biochimica et biophysica acta 1828, 2013:2855-2861.
• [9]Tomita T: Secretase inhibitors and modulators for Alzheimer's disease treatment. Expert Rev Neurother 2009, 9:661-679.
• [10]Ohki Y, Higo T, Uemura K, Shimada N, Osawa S, Berezovska O, Yokoshima S, Fukuyama T, Tomita T, Iwatsubo T: Phenylpiperidine-type gamma-secretase modulators target the transmembrane domain 1 of presenilin 1. Embo J 2011, 30:4815-4824.
• [11]Takagi S, Tominaga A, Sato C, Tomita T, Iwatsubo T: Participation of transmembrane domain 1 of presenilin 1 in the catalytic pore structure of the gamma-secretase. J Neurosci 2010, 30:15943-15950.
• [12]Kukar TL, Ladd TB, Bann MA, Fraering PC, Narlawar R, Maharvi GM, Healy B, Chapman R, Welzel AT, Price RW, et al.: Substrate-targeting gamma-secretase modulators. Nature 2008, 453:925-929.
• [13]Kukar T, Murphy MP, Eriksen JL, Sagi SA, Weggen S, Smith TE, Ladd T, Khan MA, Kache R, Beard J, et al.: Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production. Nat Med 2005, 11:545-550.
• [14]Beel AJ, Barrett P, Schnier PD, Hitchcock SA, Bagal D, Sanders CR, Jordan JB: Nonspecificity of binding of gamma-secretase modulators to the amyloid precursor protein. Biochemistry 2009, 48:11837-11839.
• [15]Barrett PJ, Sanders CR, Kaufman SA, Michelsen K, Jordan JB: NSAID-based gamma-secretase modulators do not bind to the amyloid-beta polypeptide. Biochemistry 2011, 50:10328-10342.
• [16]Herreman A, Serneels L, Annaert W, Collen D, Schoonjans L, De Strooper B: Total inactivation of gamma-secretase activity in presenilin-deficient embryonic stem cells. Nat Cell Biol 2000, 2:461-462.
• [17]Watanabe N, Image I II, Takagi S, Tominaga A, Image Image I, Tomita T, Iwatsubo T: Functional analysis of the transmembrane domains of presenilin 1: participation of transmembrane domains 2 and 6 in the formation of initial substrate-binding site of gamma-secretase. J Biol Chem 2010, 285:19738-19746.
• [18]Weihofen A, Binns K, Lemberg MK, Ashman K, Martoglio B: Identification of signal peptide peptidase, a presenilin-type aspartic protease. Science 2002, 296:2215-2218.
• [19]Friedmann E, Lemberg MK, Weihofen A, Dev KK, Dengler U, Rovelli G, Martoglio B: Consensus analysis of signal peptide peptidase and homologous human aspartic proteases reveals opposite topology of catalytic domains compared with presenilins. J Biol Chem 2004, 279:50790-50798.
• [20]Moehlmann T, Winkler E, Xia X, Edbauer D, Murrell J, Capell A, Kaether C, Zheng H, Ghetti B, Haass C, Steiner H: Presenilin-1 mutations of leucine 166 equally affect the generation of the Notch and APP intracellular domains independent of their effect on Abeta 42 production. Proc Natl Acad Sci U S A 2002, 99:8025-8030.
• [21]Annaert WG, Esselens C, Baert V, Boeve C, Snellings G, Cupers P, Craessaerts K, De Strooper B: Interaction with telencephalin and the amyloid precursor protein predicts a ring structure for presenilins. Neuron 2001, 32:579-589.
• [22]Brunkan AL, Martinez M, Wang J, Walker ES, Beher D, Shearman MS, Goate AM: Two domains within the first putative transmembrane domain of presenilin 1 differentially influence presenilinase and gamma-secretase activity. J Neurochem 2005, 94:1315-1328.
• [23]Zhao G, Cui MZ, Mao G, Dong Y, Tan J, Sun L, Xu X: gamma-Cleavage is dependent on zeta-cleavage during the proteolytic processing of amyloid precursor protein within its transmembrane domain. J Biol Chem 2005, 280:37689-37697.
• [24]Yagishita S, Morishima-Kawashima M, Tanimura Y, Ishiura S, Ihara Y: DAPT-induced intracellular accumulations of longer amyloid beta-proteins: further implications for the mechanism of intramembrane cleavage by gamma-secretase. Biochemistry 2006, 45:3952-3960.
• [25]Hashimoto T, Wakabayashi T, Watanabe A, Kowa H, Hosoda R, Nakamura A, Kanazawa I, Arai T, Takio K, Mann DM, Iwatsubo T: CLAC: a novel Alzheimer amyloid plaque component derived from a transmembrane precursor, CLAC-P/collagen type XXV. Embo J 2002, 21:1524-1534.
• [26]Qi-Takahara Y, Morishima-Kawashima M, Tanimura Y, Dolios G, Hirotani N, Horikoshi Y, Kametani F, Maeda M, Saido TC, Wang R, Ihara Y: Longer forms of amyloid beta protein: implications for the mechanism of intramembrane cleavage by gamma-secretase. J Neurosci 2005, 25:436-445.
• [27]Okochi M, Tagami S, Yanagida K, Takami M, Kodama TS, Mori K, Nakayama T, Ihara Y, Takeda M: gamma-secretase modulators and presenilin 1 mutants act differently on presenilin/gamma-secretase function to cleave abeta42 and abeta43. Cell Rep 2013, 3:42-51.
• [28]Urban S: Taking the plunge: integrating structural, enzymatic and computational insights into a unified model for membrane-immersed rhomboid proteolysis. Biochem J 2010, 425:501-512.
• [29]Hu J, Xue Y, Lee S, Ha Y: The crystal structure of GXGD membrane protease FlaK. Nature 2011, 475:528-531.
• [30]Li X, Dang S, Yan C, Gong X, Wang J, Shi Y: Structure of a presenilin family intramembrane aspartate protease. Nature 2013, 493:56-61.
• [31]Monera OD, Sereda TJ, Zhou NE, Kay CM, Hodges RS: Relationship of sidechain hydrophobicity and alpha-helical propensity on the stability of the single-stranded amphipathic alpha-helix. J Pept Sci 1995, 1:319-329.
• [32]Imamura Y, Watanabe N, Umezawa N, Iwatsubo T, Kato N, Tomita T, Higuchi T: Inhibition of gamma-secretase activity by helical beta-peptide foldamers. J Am Chem Soc 2009, 131:7353-7359.
• [33]Das C, Berezovska O, Diehl TS, Genet C, Buldyrev I, Tsai JY, Hyman BT, Wolfe MS: Designed helical peptides inhibit an intramembrane protease. J Am Chem Soc 2003, 125:11794-11795.
• [34]Takagi-Niidome S, Osawa S, Tomita T, Iwatsubo T: Inhibition of gamma-secretase activity by a monoclonal antibody against the extracellular hydrophilic loop of presenilin 1. Biochemistry 2013, 52:61-69.
• [35]Asami-Odaka A, Ishibashi Y, Kikuchi T, Kitada C, Suzuki N: Long amyloid beta-protein secreted from wild-type human neuroblastoma IMR-32 cells. Biochemistry 1995, 34:10272-10278.
• [36]Kan T, Tominari Y, Rikimaru K, Morohashi Y, Natsugari H, Tomita T, Iwatsubo T, Fukuyama T: Parallel synthesis of DAPT derivatives and their gamma-secretase-inhibitory activity. Bioorg Med Chem Lett 2004, 14:1983-1985.
• [37]Li YM, Xu M, Lai MT, Huang Q, Castro JL, DiMuzio-Mower J, Harrison T, Lellis C, Nadin A, Neduvelil JG, et al.: Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1. Nature 2000, 405:689-694.
• [38]Isoo N, Sato C, Miyashita H, Shinohara M, Takasugi N, Morohashi Y, Tsuji S, Tomita T, Iwatsubo T: Abeta42 overproduction associated with structural changes in the catalytic pore of gamma-secretase: common effects of Pen-2 N-terminal elongation and fenofibrate. J Biol Chem 2007, 282:12388-12396.
• [39]Tomita T, Takikawa R, Koyama A, Morohashi Y, Takasugi N, Saido TC, Maruyama K, Iwatsubo T: C terminus of presenilin is required for overproduction of amyloidogenic Abeta42 through stabilization and endoproteolysis of presenilin. J Neurosci 1999, 19:10627-10634.
• [40]Sato C, Takagi S, Tomita T, Iwatsubo T: The C-terminal PAL motif and transmembrane domain 9 of presenilin 1 are involved in the formation of the catalytic pore of the gamma-secretase. J Neurosci 2008, 28:6264-6271.
• [41]Thinakaran G, Regard JB, Bouton CM, Harris CL, Price DL, Borchelt DR, Sisodia SS: Stable association of presenilin derivatives and absence of presenilin interactions with APP. Neurobiol Dis 1998, 4:438-453.
• [42]Nyborg AC, Kornilova AY, Jansen K, Ladd TB, Wolfe MS, Golde TE: Signal peptide peptidase forms a homodimer that is labeled by an active site-directed gamma-secretase inhibitor. J Biol Chem 2004, 279:15153-15160.
• [43]Kitamura T, Koshino Y, Shibata F, Oki T, Nakajima H, Nosaka T, Kumagai H: Retrovirus-mediated gene transfer and expression cloning: powerful tools in functional genomics. Exp Hematol 2003, 31:1007-1014.
• [44]Tomita T, Maruyama K, Saido TC, Kume H, Shinozaki K, Tokuhiro S, Capell A, Walter J, Grunberg J, Haass C, et al.: The presenilin 2 mutation (N141I) linked to familial alzheimer disease (Volga German families) increases the secretion of amyloid beta protein ending at the 42nd (or 43rd) residue. Proc Natl Acad Sci U S A 1997, 94:2025-2030.
• [45]Watanabe N, Tomita T, Sato C, Kitamura T, Morohashi Y, Iwatsubo T: Pen-2 is incorporated into the gamma-secretase complex through binding to transmembrane domain 4 of presenilin 1. J Biol Chem 2005, 280:41967-41975.
• [46]Morohashi Y, Kan T, Tominari Y, Fuwa H, Okamura Y, Watanabe N, Sato C, Natsugari H, Fukuyama T, Iwatsubo T, Tomita T: C-terminal fragment of presenilin is the molecular target of a dipeptidic gamma-secretase-specific inhibitor DAPT (N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester). J Biol Chem 2006, 281:14670-14676.
• [47]Hofmann K, Kiso Y: An approach to the targeted attachment of peptides and proteins to solid supports. Proc Natl Acad Sci U S A 1976, 73:3516-3518.